Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure.
An extract containing predominantly pertussis toxin (PT) and filamentous haemagglutinin (FHa) was obtained from culture supernates of Bordetella pertussis by a single-step procedure using dye-ligand chromatography. The pathophysiological activities associated with the pertussis toxin component were removed by treatment with a water-soluble carbodiimide. The product was stable at 4 degrees C, was non-toxic for mice, induced high levels of IgG antibodies to both PT and FHa in vaccinated animals as judged by ELISA, and protected mice from intracerebral and intranasal challenge with B. pertussis.
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001835:Body Weight; D001886:Bordetella pertussis / Q000254:growth & development; D004797:Enzyme-Linked Immunosorbent Assay; D006388:Hemagglutinins; D007928:Lethal Dose 50; D051379:Mice; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000276:immunology*; D014121:Toxoids; D010566:Virulence Factors, Bordetella
D000907:Antibodies, Bacterial; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D014121:Toxoids; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin